Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab.

Joanne E MortimerLaura KruperJae JungLouise WongJill CooperDaphne StewartSamuel ChungKim Wai YuSanjeet DadwalYuan Yuan

Published in: Cancer chemotherapy and pharmacology (2019)

Our data continue to support an increased risk of infections with Gram-positive cocci as a potentially serious adverse event in women treated with pertuzumab and trastuzumab.

Keyphrases

epidermal growth factor receptor
metastatic breast cancer
tyrosine kinase
polycystic ovary syndrome
electronic health record
gram negative
newly diagnosed
big data
emergency department
metabolic syndrome
artificial intelligence
adverse drug